ACOR Acorda Therapeutics Inc

USD 13.21 1.30 10.923594
Icon

Acorda Therapeutics Inc (ACOR) Stock Analysis and Price Targets

COMMON STOCK | Drug Manufacturers - Specialty & Generic | NSD
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 13.21

+1.30 (+10.92)%

USD 0.02B

4.62K

N/A

N/A

Icon

ACOR

Acorda Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 13.21
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.02B

N/A

USD 13.21

Acorda Therapeutics Inc (ACOR) Stock Forecast

N/A

Based on the Acorda Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Acorda Therapeutics Inc is not available over the next 12 months. Acorda Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Acorda Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 7 negative signals. At the last closing, Acorda Therapeutics Inc’s stock price was USD 13.21. Acorda Therapeutics Inc’s stock price has changed by +9.09% over the past week, -2.86% over the past month and +13.89% over the last year.

No recent analyst target price found for Acorda Therapeutics Inc
No recent average analyst rating found for Acorda Therapeutics Inc

Company Overview Acorda Therapeutics Inc

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled le...Read More

https://www.acorda.com

420 Saw Mill River Road, Ardsley, NY, United States, 10502

111

December

USD

USA

Adjusted Closing Price for Acorda Therapeutics Inc (ACOR)

Loading...

Unadjusted Closing Price for Acorda Therapeutics Inc (ACOR)

Loading...

Share Trading Volume for Acorda Therapeutics Inc Shares

Loading...

Compare Performance of Acorda Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ACOR

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Acorda Therapeutics Inc (Sector: Drug Manufacturers - Specialty & Generic )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VTRS
Viatris Inc +0.11 (+0.93%) USD14.11B 237.70 8.88

ETFs Containing ACOR

Symbol Name ACOR's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Acorda Therapeutics Inc (ACOR) Stock

Stock Target Advisor's fundamental analysis for Acorda Therapeutics Inc's stock is Slightly Bearish.

Unfortunately we do not have enough data on ACOR's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on ACOR's stock to indicate what its average analyst target is.

ACOR stock's Price/Earning ratio is 4.69. Our analysis grades ACOR stock's Price / Earning ratio at C. This means that ACOR stock's Price/Earning ratio is above 24% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange. Based on this ACOR may be undervalued for its sector.

The last closing price of ACOR's stock was USD 13.21.

The most recent market capitalization for ACOR is USD 0.02B.

Unfortunately we do not have enough analyst data on ACOR's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Acorda Therapeutics Inc's stock.

As per our most recent records Acorda Therapeutics Inc has 111 Employees.

Acorda Therapeutics Inc's registered address is 420 Saw Mill River Road, Ardsley, NY, United States, 10502. You can get more information about it from Acorda Therapeutics Inc's website at https://www.acorda.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...